Renaissance Technologies LLC Sells 532,545 Shares of Precigen, Inc. (NASDAQ:PGEN)

Renaissance Technologies LLC reduced its stake in Precigen, Inc. (NASDAQ:PGEN - Free Report) by 33.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,067,645 shares of the biotechnology company's stock after selling 532,545 shares during the quarter. Renaissance Technologies LLC owned 0.36% of Precigen worth $1,196,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Stifel Financial Corp raised its stake in shares of Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 15,680 shares during the period. State Street Corp grew its holdings in shares of Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company's stock worth $2,720,000 after buying an additional 29,253 shares in the last quarter. Barclays PLC raised its position in Precigen by 190.4% in the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company's stock valued at $179,000 after buying an additional 124,141 shares during the last quarter. Geode Capital Management LLC boosted its position in Precigen by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company's stock worth $3,075,000 after acquiring an additional 149,829 shares during the last quarter. Finally, Synovus Financial Corp grew its stake in shares of Precigen by 100.0% during the 3rd quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company's stock worth $93,000 after acquiring an additional 49,065 shares in the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Stock Performance

PGEN traded down $0.04 during trading on Monday, reaching $1.54. 46,234 shares of the stock were exchanged, compared to its average volume of 1,252,254. The stock's 50 day moving average price is $1.58 and its two-hundred day moving average price is $1.27. Precigen, Inc. has a twelve month low of $0.65 and a twelve month high of $2.17. The stock has a market cap of $453.08 million, a P/E ratio of -2.79 and a beta of 1.70.

Precigen (NASDAQ:PGEN - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. The company had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.30 million. Equities research analysts predict that Precigen, Inc. will post -0.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

PGEN has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and set a $6.00 target price on shares of Precigen in a report on Thursday, March 20th. JMP Securities restated a "market outperform" rating and issued a $5.00 price objective on shares of Precigen in a report on Tuesday, January 14th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $7.00.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.